SEARCH:   Advanced

Blood, 15 January 2005, Vol. 105, No. 2, pp. 481-488. Prepublished online as a Blood First Edition Paper on June 22, 2004; DOI 10.1182/blood-2004-01-0326. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-01-0326v1 105/2/481    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bradstock, K. F. Articles by Young, G. A. R. Search for Related Content PubMed PubMed Citation Articles by Bradstock, K. F. Articles by Young, G. A. R. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine Kenneth F. Bradstock, Jane P. Matthews, Raymond M. Lowenthal, Heather Baxter, John Catalano, Timothy Brighton, Devinder Gill, Paul Eliadis, Douglas Joshua, Paul Cannell, Anthony P. Schwarer, Simon Durrant, Anne Gillett, Jerry Koutts, Kerry Taylor, John Bashford, Christopher Arthur, Arno Enno, Lindsay Dunlop, Jeff Szer, Michael Leahy, Surender Juneja, and Graham A. R. Young, for the Australasian Leukaemia and Lymphoma Group From the Department of Haematology, Westmead Hospital, Westmead, NSW, Australia; Statistical Centre, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Royal Hobart Hospital, Hobart, TAS, Australia; Monash Medical Centre, Clayton, VIC, Australia; St George Hospital, Kogarah, NSW, Australia; Princess Alexandra Hospital, Woolloongabba, QLD, Australia; Wesley Medical Centre, Brisbane, QLD, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Royal Perth Hospital, Perth, WA, Australia; Alfred Hospital, Prahran, VIC, Australia; Royal Brisbane Hospital, Herston, QLD, Australia; Mater Hospital, South Brisbane, QLD, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia; Mater Hospital, Newcastle, NSW, Australia; Liverpool Hospital, Liverpool, NSW, Australia; Royal Melbourne Hospital, Melbourne VIC, Australia; and Fremantle Hospital, Fremantle, WA, Australia. The value of administering sequential courses of chemotherapy containing high-dose cytarabine in both induction and consolidation therapy for acute myeloid leukemia (AML) has not been assessed in a prospective randomized trial. Two hundred ninety-two AML patients aged 15 to 60 years were enrolled in the Australasian Leukaemia and Lymphoma Group (ALLG) AML trial number 7 (M7) protocol to evaluate this question. All received induction therapy with the ICE protocol (idarubicin 9 mg/m2 x 3; cytarabine 3 g/m2 twice a day on days 1, 3, 5, 7; etoposide 75 mg/m2 x 7). Complete remission was achieved in 234 (80%) patients. Two hundred two patients in remission were then randomized to either a further identical cycle of ICE or 2 attenuated courses (cytarabine 100 mg/m2 daily x 5, idarubicin x 2, etoposide x 5 [IcE]). ICE consolidation therapy was more toxic than IcE, however, the treatment-related death rate was not significantly different. There was no difference between the 2 consolidation arms for relapse-free survival at 3 years (49% for ICE vs 46% for IcE; P = .66), survival following randomization (61% vs 62%; P = .91), or the cumulative incidence of relapse (43% vs 51%; P = .31), and there was no difference within cytogenetic risk groups. Intensive induction chemotherapy incorporating high-dose cytarabine results in high complete remission rates, but further intensive consolidation treatment does not appear to confer additional benefit. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. A. Dawson, S. Avery, Z. K. McQuilten, M. J. Bailey, J. Shortt, M. N. Polizzotto, E. M. Wood, and M. F. Cole-Sinclair Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough? Haematologica, July 1, 2007; 92(7): 996 - 997. [Abstract] [Full Text] [PDF] M. Brune, S. Castaigne, J. Catalano, K. Gehlsen, A. D. Ho, W.-K. Hofmann, D. E. Hogge, B. Nilsson, R. Or, A. I. Romero, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood, July 1, 2006; 108(1): 88 - 96. [Abstract] [Full Text] [PDF] T. Kober, N. Skoetz, S. Trelle, J. Bohlius, and A. Engert Third Biannual Report of the Cochrane Haematological Malignancies Group J Natl Cancer Inst, August 17, 2005; 97(16): E2 - E. [Full Text] M. S. Tallman New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents Hematology, January 1, 2005; 2005(1): 143 - 150. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020